Sugi Predict

Sugi Predict / Compounds / SCHEMBL17419151

SCHEMBL17419151

SCHEMBL17419151

Cn1c(=O)oc2cc(B3OC(C)(C)C(C)(C)O3)c(F)cc21

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 2/20 0.36
▸ BTK Q06187 2/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ PKM P14618 4/20 0.36
▸ TSHR P16473 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ PSMD14 O00487 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ GPR55 Q9Y2T6 2/20 0.33
▸ DDB1 Q16531 1/20 0.33
▸ CRBN Q96SW2 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ CACNA1G O43497 1/20 0.32
▸ CACNA1H O95180 1/20 0.32
▸ CACNA1I Q9P0X4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL782914 0.94 JAK2 (0.36) JAK2BTKMEN1KMT2APKM
SCHEMBL16361868 0.84 LMNA (0.38) JAK2BTKMEN1KMT2APKM
SCHEMBL16362390 0.82 KDM4E (0.34) MEN1KMT2APKMTSHRALDH1A1
SCHEMBL16362043 0.82 LMNA (0.38) JAK2BTKMEN1KMT2APKM
SCHEMBL28700816 0.81 HTT (0.39) PKMTSHRALDH1A1HPGDLMNA
SCHEMBL782863 0.81 LMNA (0.37) JAK2BTKMEN1KMT2APKM
SCHEMBL16362027 0.80 KDM4E (0.34) MEN1KMT2APKMTSHRALDH1A1
SCHEMBL16362030 0.79 DDB1 (0.38) MEN1KMT2APKMTSHRALDH1A1
SCHEMBL782545 0.77 DDB1 (0.42) PKMTSHRALDH1A1HPGDLMNA
SCHEMBL16362076 0.76 DDB1 (0.40) MEN1KMT2APKMTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11401272-B2 Heterocyclic compounds as LSD1 inhibitors INCYTE CORPORATION (US) 2022-08-02 — — US disclosed
CN-107660205-B Heterocyclic compounds as LSD1 inhibitors 因赛特公司 2021-08-27 — — CN disclosed
US-20200392143-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS INCYTE CORPORATION 2020-12-17 — — US disclosed
US-20200392143-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS INCYTE CORPORATION 2020-12-17 — — US disclosed
US-10800779-B2 Heterocyclic compounds as LSD1 inhibitors INCYTE CORPORATION (US) 2020-10-13 — — US disclosed
US-10800779-B2 Heterocyclic compounds as LSD1 inhibitors INCYTE CORPORATION (US) 2020-10-13 — — US disclosed
US-10640503-B2 Imidazopyridines and imidazopyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2020-05-05 — — US disclosed
US-10640503-B2 Imidazopyridines and imidazopyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2020-05-05 — — US disclosed
EP-3626720-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS Incyte Corporation (US) 2020-03-25 — — EP disclosed
EP-3626720-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS Incyte Corporation (US) 2020-03-25 — — EP disclosed
WO-2016161282-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2016-10-06 — — WO disclosed
WO-2016161282-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2016-10-06 — — WO disclosed
US-20160009720-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 — — US disclosed
US-20160009720-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 — — US disclosed
US-20160009720-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 — — US disclosed
WO-2016007731-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2016-01-14 — — WO disclosed
WO-2016007736-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2016-01-14 — — WO disclosed
US-20160009712-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 — — US disclosed
US-20160009712-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 — — US disclosed
US-20160009712-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11401272-B2 Heterocyclic compounds as LSD1 inhibitors KDM1B, KDM1A, DOT1L JAK2 2359/4885BTK 3844/4885MEN1 1983/4885
US-20160009720-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS KDM1B, KDM2A, KDM1A JAK2 1212/4885BTK 3503/4885MEN1 2992/4885
US-20200392143-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS KDM1B, KDM1A, DOT1L JAK2 2359/4885BTK 3844/4885MEN1 1983/4885
US-20160009712-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS KDM5A, KDM1A, KDM1B JAK2 948/4885BTK 2875/4885MEN1 2686/4885
US-10800779-B2 Heterocyclic compounds as LSD1 inhibitors KDM1B, KDM1A, DOT1L JAK2 2359/4885BTK 3844/4885MEN1 1983/4885
US-10640503-B2 Imidazopyridines and imidazopyrazines as LSD1 inhibitors KDM5A, KDM1A, KDM1B JAK2 331/4885BTK 2856/4885MEN1 2470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.